379-54-4

Usage

Uses

Used in Chemical Synthesis:
4,4'-(Chloro(phenyl)methylene)bis(fluorobenzene) is used as an intermediate substance in various chemical reactions, playing a crucial role in the synthesis of more complex molecules. Its unique structure allows it to participate in a range of reactions, making it a valuable component in the creation of new compounds.
Used in Materials Science Research:
In the field of materials science, 4,4'-(Chloro(phenyl)methylene)bis(fluorobenzene) is employed as a research compound to study the properties and behavior of materials at the molecular level. Its reactivity and stability contribute to the understanding of how different materials interact and can be manipulated for specific applications.
Used in Pharmaceutical Industry:
4,4'-(Chloro(phenyl)methylene)bis(fluorobenzene) is used as a building block in the development of pharmaceutical compounds. Its structural characteristics make it a potential candidate for the creation of new drugs, particularly in the areas of medicinal chemistry and drug design.
Used in Industrial Applications:
In industrial settings, 4,4'-(Chloro(phenyl)methylene)bis(fluorobenzene) is utilized in the production of various materials and products. Its versatility in chemical reactions allows it to be incorporated into the manufacturing processes of a wide range of industries, from plastics to electronics.

InChI:InChI=1/C19H13ClF2/c20-19(14-4-2-1-3-5-14,15-6-10-17(21)11-7-15)16-8-12-18(22)13-9-16/h1-13H

Upstream product

• 379-55-5 bis(4-fluorophenyl)phenylmethanol 
• 93-58-3 benzoic acid methyl ester 

Downstream Products

• 103193-96-0 CDD₃₅₄₃ 
• 90173-62-9 Trifluoro-acetic acid bis-(4-fluoro-phenyl)-phenyl-methyl ester 
• 289656-82-2 bis(4-fluorophenyl)phenylacetonitrile 

Relevant academic research and scientific papers

Novel inhibitors of the gardos channel for the treatment of sickle cell disease

Sickle cell disease (SCD) is a hereditary condition characterized by deformation of red blood cells (RBCs). This phenomenon is due to the presence of abnormal hemoglobin that polymerizes upon deoxygenation. This effect is exacerbated when dehydrated RBCs experience a loss of both water and potassium salts. One critical pathway for the regulation of potassium efflux from RBCs is the Gardos channel, a calcium-activated potassium channel. This paper describes the synthesis and biological evaluation of a series of potent inhibitors of the Gardos channel. The goal was to identify compounds that were potent and selective inhibitors of the channel but had improved pharmacokinetic properties compared to 1, Clotrimazole. Several triarylamides such as 10 and 21 were potent inhibitors of the Gardos channel (IC50 of 10 nM) and active in a mouse model of SCD. Compound 21 (ICA-17043) was advanced into phase 3 clinical trials for SCD.

TREATMENT METHODS USING TRIARYL METHANE COMPOUNDS

The use of novel inhibitors of potassium flux is disclosed for the treatment of inflammatory processes, such as multiple sclerosis, insulin-dependent (type I) diabetes mellitus, rheumatoid arthritis, peripheral neuritis and pulmonary hypertension. The com

Influence of some novel N-substituted azoles and pyridines on rat hepatic CYP3A activity

A series of N-substituted heteroaromatic compounds structurally related to clotrimazole was synthesized, and the effects of these compounds on ethosuximide clearance in rats were determined as a measure of their abilities to induce cytochrome P4503A (CYP3A) activity. Ethosuximide clearance and in vitro erythromycin N-demethylase activity were shown to correlate. In this series, imidazole or other related heteroaromatic 'head groups' were linked to triphenylmethane or other phenylmethane derivatives. Within the series, it was found that 1-triphenylmethane-substituted imidazoles elicited the greatest increase in CYP3A activity, and that among the triphenylmethyl-substituted imidazoles, the highest activities were achieved by the substitution of F- or Cl- in either the meta or para position of one of the phenyl rings. Diphenylmethylsubstituted pyridine was effectively devoid of activity. Compounds eliciting the largest increase in CYP3A activity (viz. 1-[(3-fluorophenyl)diphenylmethyl]imidazole, 1-[(4- fluorophenyl)diphenylmethyl]imidazole, and 1-[tri-(4- fluorophenyl)methyl]imidazole) produced little or no increase in ethoxyresorufin O-dealkylase (EROD) activity (i.e. CYP1A), whereas benzylimidazole, which elicited only a small increase in CYP3A activity, produced an almost 9-fold increase in CYP1A activity. For a series of eleven compounds exhibiting a wide range of influence on CYP3A activity, a positive correlation was found between ethosuximide clearance and hepatic CYP3A mRNA levels.

Synthesis and antifungal activity of a series of difluorotritylimidazoles

1-[(2-Fluorophenyl)(4-fluorophenyl)phenylmethyl]-1H-imidazole (flutrimazole, UR-4056, CAS 119006-77-8) (15) was selected among a series of mono-, di- and trifluorotrityl-imidazole antifungal agents as the most potent fluorine containing analogue of clotrimazole.